- Disease-modifying treatment approaches in Huntington disease: Past and future2022 | First Faculty of Medicine
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS2017 | First Faculty of Medicine
- Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment2014 | First Faculty of Medicine
- Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study2019 | First Faculty of Medicine
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | First Faculty of Medicine
- Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis2007 | First Faculty of Medicine
- Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis2007 | Faculty of Physical Education and Sport
- Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic2021 | Third Faculty of Medicine
- Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers2023 | First Faculty of Medicine
- The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe2023 | First Faculty of Medicine
- Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Third Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study2019 | Faculty of Medicine in Hradec Králové
- Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement2021 | First Faculty of Medicine
- Basic changes in the guidelines for dyslipidemia management from the year 20192020 | Faculty of Medicine in Pilsen
- Lipid-modifying therapies of tomorrow - what will they be like?2012 | First Faculty of Medicine
- Statin intolerance - finding practical solutions2017 | First Faculty of Medicine
- Predictors of treatment switching in the Big Multiple Sclerosis Data Network2023 | First Faculty of Medicine
- Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine2016 | First Faculty of Medicine
- Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM2013 | First Faculty of Medicine
- ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis2018 | First Faculty of Medicine
- New trends in the treatment of diabetic neuropathy2012 | Faculty of Medicine in Pilsen
- Preventing lymphocyte migration may mean keeping ahead of multiple sclerosis progression2021 | First Faculty of Medicine
- Treatment of diabetic neuropathy2012 | Faculty of Medicine in Pilsen
- Optimal Alzheimer's disease detection and diagnosis under the sex and gender lens: a crucial step towards precision neurology2021 | Second Faculty of Medicine
- A perspective on multi-target drugs for Alzheimer's disease2020 | Publication without faculty affiliation
- Modern drug therapy in neurology2015 | Third Faculty of Medicine, Second Faculty of Medicine
- Pharmacotherapy of stable angina pectoris2011 | First Faculty of Medicine, Third Faculty of Medicine
- Diagnostic difficulties with an atypical form of non-Hodgkin's lymphoma in a child2000 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy2020 | Second Faculty of Medicine
- Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study2022 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine